Running title: Sex-based TMB predicts response to immunotherapies. Abstract 1 Anti-programmed cell death protein 1 (PD-1) therapy provided superior benefits in skin 2 cutaneous melanoma (SKCM), but only a minority of patients responded. As SKCM 3 had sex-based immunological differences, we sought to explore the potential 4 interactions between sex and clinical responses to anti-PD-1 therapy in SKCM. We 5 found that sex had significant effects on anti-PD-1 therapy. Tumor mutation burden 6 (TMB) and neoantigen burden significantly correlated with the clinical responses to 7 anti-PD-1 therapy only in males. Meanwhile, we recruited The Cancer Genome Atlas 8 (TCGA) database to explore sex-based differences of the tumor microenvironment 9 (TME) in SKCM. We observed that males with high TMB, especially in conjunction 10 with interferon-gamma (IFN-γ) signaling, significantly correlated with increased PD-11 L1 expression, major histocompatibility complex (MHC) class I gene expression, and 12 the infiltration of cytotoxic T lymphocytes (CTLs). In addition, TMB and anti-PD-1 13 efficacy in SKCM each correlated with homologous recombination repair (HRR) gene 14 BRCA2 mutations, but only in males. Taken together, these data revealed that in SKCM, 15 high TMB correlated with prominent immunotherapeutic TME only in males, and that 16 gender should be taken into account when predicting the efficacy of anti-PD-1 therapy 17 for SKCM.
SKCM patients in
and 44 SKCM samples in Riaz et al study 1 (9). Pre-therapy biopsies from SKCM patients were determined by whole-exome 2 sequencing (WES). Given the small number of samples in these cohorts, we integrated 3 the data into one Cell-SKCM dataset according to their common features, such as 4 patients' TMB, neoantigens, gender, clinical response to anti-PD-1 therapy, histology, 5 and age (n=78; Fig. 1A and B ; Table S1 ). In addition, we also recruited TCGA-SKCM 6 datasets containing multidimensional non-immunotherapeutic characteristics to further 7 explore the tumor immune escape in Cell-SKCM cohort (n=472; Fig. 1C ; Table S1 ). 8 Importantly, in Cell-SKCM, the quantity and range of TMB (i.e., the total number of 9 somatic non-synonymous single nucleotide variations) were similar to that in the 10 TCGA-SKCM dataset (P=0.71; Fig. S1A ), suggesting the homogeneity of these two 11 cohorts as previously described (12, 30) . 12 13 Sex differences correlated with TMB and neoantigen burden in patients with 14 differential response to anti-PD-1 therapy 15 Compared with females, TMB was markedly increased in males in the TCGA-SKCM 16 cohort; a similar trend was observed for the Cell-SKCM cohort although the difference 17 was not statistically significant possibly because of smaller sample size (Fig. S1B ).
18
Consistent with these, males but not females displaying good therapeutic responses 19 (CR/PR: complete/partial response to anti-PD-1 therapy) showed significantly higher 20 TMB compared with those who had no response (SD/PD: stable/progressive disease 21 for anti-PD-1 therapy) in Cell-SKCM cohort ( Fig. 2A ). Receiver operator characteristic (ROC) curves also validated high associations between TMB and clinical efficacy to 1 PD-1 blockade in males (AUC=0.74, P=0.005; Fig. 2B ). The discovery of the sex-based 2 immunotherapeutic differences of TMB was consistent with neoantigen burden 3 (AUC=0.73, P=0.007; Fig. 2D and E); neoantigens are generated as a consequence of 4 TMB and can elicit effective immune responses (12, 31) . 5 To further reveal the potential clinical usefulness of TMB and neoantigen burden 6 for predicting PD-1 blockade response, we used the Youden index (7, 11, 12) to 7 determine the optimum cutoff point. The cutoff points of both TMB and neoantigens 8 were significantly lower in males than in females, suggesting that these two biomarkers 9 were more sensitive to males for predicting PD-1 blockade efficacy ( Fig. 2B and E) . Table S2 ). Using multivariate logistic regression analysis with 14 adjustment for age, we also observed a significant association between male-based 15 TMB and clinical efficacy to anti-PD-1 therapy (Odds Ratio=7.77, P=0.01; Table S2 ).
16
Of note, given its significant correlation with TMB, neoantigens were not included in 17 the multivariate regression analysis ( Fig. S2A and B ).
18
To assess the clinical utility of TMB in Cell-SKCM cohort, patients were classified 19 into four TMB-defined groups based on Youden index-associated cutoff points (11): 20 females with high TMB (F_High), ≥ 402.5; females with low TMB (F_Low), < 402.5; 21 males with high TMB (M_High), ≥ 265.5; males with low TMB (M_Low), < 265.5.
The same methodology applied to neoantigen-defined groups. This stratification 1 scheme revealed that the percentage of overall survival (OS) was significantly better in 2 males with high TMB and neoantigen burden (P=0.03 and P=0.05, respectively; Fig.   3 S3A-D). As Cell-SKCM cohort lacks transcriptomic profile, we turned to multidimensional 8 TCGA-SKCM datasets, which carry both genomic and matched transcriptomic profiles, 9 to further explore the sex-based tumor immune evasion. We stratified the TCGA-10 SKCM samples into four TMB-defined groups as described above for the Cell-SKCM 11 cohort ( Fig. S1C ; Table S3 ), observing significant sex-based differences in neoantigens 12 in different groups, consistent with a tight correlation between TMB and neoantigens 13 ( Fig. S2C and D) . supports the notion that IFN-γ signaling and related gene signatures play important 21 roles in mediating tumor rejection for ICB therapies and can predict clinical response to PD-1 blockade in melanoma (7, 10, 15, 16) . Finally, a T cell-inflamed gene 1 expression profile (GEP) has been described for predicting PD-1 blockade response 2 across multiple cancers (7, 11) . Indeed, T cell-inflamed GEP score tended to increase 3 in males with high TMB (P=0.07; Fig. S4A ). The low statistical significance might be 4 attributed to the fact that T cell-inflamed GEP (as a pan-tumor biomarker) is not as 5 specific and effective as IFN-γ signatures in predicting PD-1 blockade efficacy in 6 SKCM (7). The presence of cytotoxic T lymphocytes (CTLs) is an important biomarker for 5 predicting response to ICB therapies (18, 19) . We therefore examined the crucial 6 markers of CTLs (GZMA, GZMB, CD8A, CD8B, and PRF1) as described (19), finding 7 that CTLs infiltration tended to increase in males with high TMB compared with low 8 TMB (P=0.21; Fig. S4B ).
9
CTLs infiltration can be affected by its dysfunctional state and 10 immunosuppressive factors (19) . Using Tumor Immune Dysfunction and Exclusion 11 (TIDE) algorithm (19), we found that males with high TMB displayed significantly 12 decreased exclusions of T cells (P=0.0067) but no T cell dysfunction, suggesting that 13 the infiltrating CTLs were functional and thus beneficial to these patients ( Fig. 6A and   14 B). Consistent with this, these patients also showed decreased TIDE scores and 15 increased IFN-γ scores (P=0.0069 and P=0.0059, respectively; Fig. 6C and D), which 16 are known to correlate with the efficacy of anti-PD-1 therapy. 17 18 BRCA2 mutation correlated with therapeutic response only in males 19 Melanoma is one of the most typical mutation-caused malignant tumors and shows a 20 higher prevalence of C>T mutations through ultraviolet exposure and other lesions (33).
21
C>T mutations, suggesting no gender bias in ultraviolet-induced mutation signature 1 ( Fig. S5A and B ).
2
In contrast, Gene Set Enrichment Analysis (GSEA) showed prominent enrichment 3 of pathways associated with cell cycle and DNA replication only in males with high 4 TMB ( Fig. 3A; Fig. 7A and B) , which could potentially facilitate the accumulation of 5 DNA mutation and damage. 6 We further examined the DNA damage response (DDR) pathways essential for 7 genomic integrity (34), focusing on the genes whose mutations can induce a 8 hypermutational phenotype and durable clinical benefits from ICB therapies, such as 9 base excision repair (POLE), MMR (MSH2, MSH6, ARID1A, MLH1, and PMS2) and 10 HRR (BRCA2) (34, 35) . We found that mutations in POLE and MMR-related genes 11 were increased in both females and males with high TMB ( Fig. 7C and D). However, 12 BRCA2 mutations were specifically enriched in males with clinical benefits from anti-13 PD-1 therapy (P=0.009) and with high TMB (P=0.006), indicating that males who had 14 high TMB and BRCA2 mutations were more sensitive to anti-PD-1 therapy in SKCM 15 ( Fig. 7E and F ). Furthermore, to assess the biologic and oncogenic effects of these 16 genetic alterations, we performed the analysis with MutationMapper (36), PolyPhen-2 17 (37), and SIFT (38). The result revealed that most of these genetic mutations (POLE, 1 We have found that only in males was high TMB correlated with other known 2 biomarkers for predicting PD-1 blockade efficacy in SKCM ( Fig. S6A and B ). To begin 3 to explore the molecular basis of this gender-specific phenomenon, we focused on ERβ, 4 the predominant subtype of ERs in melanoma (39). ERβ acts as a tumor suppressor (39) 5 partly via promoting IFN-γ secretion in the TME (1, 40), and its expression decreases 6 as melanoma progresses. We noted a marked decrease in ERβ expression in females 7 with high TMB compared with males with high TMB (Fig. S7A and B) , and there were 8 tighter associations between ERβ and IFN-γ expression in females with high TMB than 9 males with high TMB (r=0.24, r= -0.03, respectively; Fig. S7C ). Thus, in females with 10 high TMB, ERβ and IFN-γ expression were compromised, which might help disrupt 11 the correlation of TMB and other biomarkers with the therapeutic efficacy, and this 12 disruption may be exacerbated after menopause, when the estrogen levels decline 13 rapidly (41). Of note, in the female SKCM patients, PD-L1 expression and IFN-γ score 14 also decreased with age, which could further disrupt the above-mentioned correlation Very little is known about sex-associated differences for ICB therapies. Although a 19 recent meta-analysis reported that males could derive greater value from ICB therapies 20 than females in multiple cancers (23), their conclusion is controversial (26-28). For 21 instance, Wallis and colleagues' meta-analysis collecting more clinical trials showed no statistically significant differences between patient sex and immunotherapy efficacy in 1 many advanced cancers (26) . Another recent study also reported no significant 2 association of sex with the efficacy of immunotherapies in metastatic renal cell 3 carcinoma (28). A caveat of these studies is that anti-CTLA-4 and anti-PD-1 4 immunotherapeutic cohorts were not separately analyzed in each cancer type, which 5 might have obscured the effects of sex (14, 42).
Correlations of estrogen and estrogen receptors (ERs) with tumor immune escape in SKCM

6
PD-1 blockade is effective to only a minority of melanoma patients, and the 7 mechanisms are unclear (8, 9, 43) . Note that in the previous studies, the gender factor 8 has been ignored (8, 9, 22, 23, 26, 43) . Importantly, for melanoma patients treated with 9 anti-PD-1 therapy, we showed that high TMB correlated with durable clinical benefits 10 only in males, providing a partial explanation for the heterogeneity in the patient 11 responses.
12
One limitation of our study lies in the small number of PD-1 blockade samples 13 from different clinical trials, but our datasets are much more homogeneous than 14 previous studies (8, 9, 22, 23, 26, 43) and thus more reliable for discovering the 15 determinants of therapeutic efficacy. In addition, we recruited multidimensional 
